Use of senicapoc for treatment of neuropathic pain
AssigneeParacelsus Neuroscience I, LLC
InventorsRoland Staal, Thomas Möller
Life of this patent
Estimating the term…
Abstract
A method is disclosed of treating pain with senicapoc, a potent Ca2+-activated K+ channel, KCa3.1 antagonist in CNS-resident microglia. Senicapoc is shown to cause in a decrease of IL-1β and NO release from microglia cells vivo and in vitro. Because of contribution of KCa3.1 to neuropathological processes, senicapoc is useful in the treatment of chronic, neuropathic, visceral, and inflammatory pain and the reversal of tactile allodynia.
Claims2
A method of inhibiting KCa3.1 calcium activated potassium channels on microglia in the central nervous system, satellite glia in the dorsal root ganglia or peripheral immune cells in a mammal suffering from neuropathic pain consisting of the administration of an amount of senicapoc sufficient to achieve at least 50% inhibition of the potassium channel KCa3.1 on microglia in the central nervous system, satellite glia in the dorsal root ganglia or peripheral immune cells, wherein the inhibition of microglia KCa3.1 channels treats neuropathic pain.
Dependencies are inferred from the claim text.